Small-molecule CGRP receptor antagonists may pose a risk during stroke


Vidyard Video

CGRP receptor antagonists to treat migraine don’t boost stroke risk, but they could worsen stroke outcomes, according to a new animal study.

“It turns out that these drugs make the blood vessels of the brain dysfunctional, such that the collateral channels that bring in blood to the region that is having the stroke are impaired,” explains the study’s lead author, Cenk Ayata, MD, associate professor of neurology and radiology at Harvard Medical School, Boston.

In an interview, Alan M. Rapoport, MD, clinical professor of neurology at the University of California, Los Angeles, talks with Dr. Ayata about his study findings, and about CGRP receptor antagonists’ potential effects if a patient has an ischemic event.

This article was updated 4/21/20.

Recommended Reading

Do urgent care centers use optimal medications for acute migraine?
MDedge Neurology
How can neurologists diagnose and treat menstrual migraine?
MDedge Neurology
When is preventive treatment of migraine appropriate?
MDedge Neurology
Pandemic necessitates new strategies to treat migraine
MDedge Neurology
How do neurologists choose an acute treatment for migraine?
MDedge Neurology